The radiochemistry core will continue to provide the radiopharmaceuticals, radiopharmaceutical quality control, metabolite analysis and regulatory documentation required by the projects to fulfill the goals of the research described in this application.
The specific aims are to produce C, F, and O, and to use these radionuclides to make the radiopharmaceuticals: 2-[C]-thymidine;[C]-verapamil;[C]-doxorubicin;[C]-carbon dioxide;[F]-2-fluoro-2-deoxy-D-glucose;[F]-fluoromisonidazole;[F]-fluorothymidine;16-alpha-[F]-fluoroestradiol;and [O]-water. The radiochemists are responsible for assuring the radiochemical purity and pharmaceutical quality of all products for in vivo studies and for compliance with all regulations regarding radiation and pharmaceutical safety.
|Link, Jeanne M; Krohn, Kenneth A; O'Hara, Matthew J (2017) A simple thick target for production of 89Zr using an 11MeV cyclotron. Appl Radiat Isot 122:211-214|
|Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res 23:407-415|
|Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655|
|Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200|
|Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S|
|Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with ¹?F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8|
|Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7|
|Kurland, Brenda F; Muzi, Mark; Peterson, Lanell M et al. (2016) Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. J Nucl Med 57:226-30|
|Jackson, Pamela R; Juliano, Joseph; Hawkins-Daarud, Andrea et al. (2015) Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practice. Bull Math Biol 77:846-56|
|Peck, M; Pollack, H A; Friesen, A et al. (2015) Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging 59:95-104|
Showing the most recent 10 out of 193 publications